LRRK2 inhibitor

SI-6893

LRRK2 inhibitor, >98% (HPLC)

IUPAC Name : (3R,4R)-4-(4-(3-Chloro-7-((1-((R)-2,2-difluorocyclopropyl)-4-methyl-1H-pyrazol-5-yl)amino)naphthalen-2-yl)piperidin-1-yl)-4-methyltetrahydrofuran-3-ol

Price And Availability
Pack Size	Price in USD	Add To Shopping Cart	Availability	Shipping Status
5MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
10MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
25MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
50MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
100MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026

Applications : This is a brain‑penetrant, highly selective LRRK2 inhibitor emerging from a structure‑enabled hit‑to‑lead campaign for Parkinson’s disease. It combines excellent kinome selectivity, good oral bioavailability, low projected human doses, and strong CNS penetration with minimal efflux. Stereochemical design elements increase polarity and H‑bond donor count, delivering enhanced potency and selectivity while maintaining a CNS‑friendly profile suitable for advancement as a candidate‑quality LRRK2 inhibitor.

References : Keylor H. M. et al.: J. Med. Chem., 65(1), 838-856, 2022.

Storage : Keep container tightly closed under nitrogen or argon and refrigerate for long-term shelf life.

Caution : In case of contact with skin or eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing and gloves.